Multivalent & multifunctional ligands to β-amyloid

YoungSoo Kim, Ji Hoon Lee, Jiyeon Ryu, Dong Jin Kim

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Ligands selectively targeting β-amyloid in the living brain are promising candidates of therapeutics and early diagnosis tools for Alzheimer's disease. Among the major stages of β-amyloid aggregation, monomers and oligomers are excellent targets to reduce neurotoxic brain damages for prevention of the disease progression, while oligomers and fibrils, abundant in the late stage of the disease, are pathological objectives to develop reliable imaging probes. So far, there have been many efforts to develop a wide variety of monovalent β-amyloid ligands such as thioflavin T, PIB, FDDNP, curcumin, and tramiprosate. However, pathology of Alzheimer's disease is not fully understood yet so that there is currently no cure and further investigations on Alzheimer's disease are needed. For past several years, multivalent β-amyloid ligands have offered an alternative route by enhancing binding affinity of drug candidates. In addition, it has been revealed that not only neurotoxicity due to the protein misfolding but also other factors are involved in the β-amyloid cascade such as oxidative stress, inflammation, metal chelation, and several types of neurotransmitters. Thus, there have been numerous studies to improve binding affinities of single β-amyloid ligands via adopting multivalent effects or to develop drug candidates targeting multiple stages of the pathological cascade. In this review, multivalent and multifunctional β-amyloid ligands and their promising aspects as an alternative approach to Alzheimer's disease are discussed.

Original languageEnglish
Pages (from-to)637-658
Number of pages22
JournalCurrent Pharmaceutical Design
Volume15
Issue number6
DOIs
Publication statusPublished - 2009 May 25

Fingerprint

Amyloid
Ligands
Alzheimer Disease
Curcumin
Brain
Drug Delivery Systems
Neurotransmitter Agents
Disease Progression
Early Diagnosis
Oxidative Stress
Metals
Pathology
Inflammation
Pharmaceutical Preparations
Proteins

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Kim, YoungSoo ; Lee, Ji Hoon ; Ryu, Jiyeon ; Kim, Dong Jin. / Multivalent & multifunctional ligands to β-amyloid. In: Current Pharmaceutical Design. 2009 ; Vol. 15, No. 6. pp. 637-658.
@article{25b40531531d4519a5d5de484b48785a,
title = "Multivalent & multifunctional ligands to β-amyloid",
abstract = "Ligands selectively targeting β-amyloid in the living brain are promising candidates of therapeutics and early diagnosis tools for Alzheimer's disease. Among the major stages of β-amyloid aggregation, monomers and oligomers are excellent targets to reduce neurotoxic brain damages for prevention of the disease progression, while oligomers and fibrils, abundant in the late stage of the disease, are pathological objectives to develop reliable imaging probes. So far, there have been many efforts to develop a wide variety of monovalent β-amyloid ligands such as thioflavin T, PIB, FDDNP, curcumin, and tramiprosate. However, pathology of Alzheimer's disease is not fully understood yet so that there is currently no cure and further investigations on Alzheimer's disease are needed. For past several years, multivalent β-amyloid ligands have offered an alternative route by enhancing binding affinity of drug candidates. In addition, it has been revealed that not only neurotoxicity due to the protein misfolding but also other factors are involved in the β-amyloid cascade such as oxidative stress, inflammation, metal chelation, and several types of neurotransmitters. Thus, there have been numerous studies to improve binding affinities of single β-amyloid ligands via adopting multivalent effects or to develop drug candidates targeting multiple stages of the pathological cascade. In this review, multivalent and multifunctional β-amyloid ligands and their promising aspects as an alternative approach to Alzheimer's disease are discussed.",
author = "YoungSoo Kim and Lee, {Ji Hoon} and Jiyeon Ryu and Kim, {Dong Jin}",
year = "2009",
month = "5",
day = "25",
doi = "10.2174/138161209787315648",
language = "English",
volume = "15",
pages = "637--658",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

Multivalent & multifunctional ligands to β-amyloid. / Kim, YoungSoo; Lee, Ji Hoon; Ryu, Jiyeon; Kim, Dong Jin.

In: Current Pharmaceutical Design, Vol. 15, No. 6, 25.05.2009, p. 637-658.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Multivalent & multifunctional ligands to β-amyloid

AU - Kim, YoungSoo

AU - Lee, Ji Hoon

AU - Ryu, Jiyeon

AU - Kim, Dong Jin

PY - 2009/5/25

Y1 - 2009/5/25

N2 - Ligands selectively targeting β-amyloid in the living brain are promising candidates of therapeutics and early diagnosis tools for Alzheimer's disease. Among the major stages of β-amyloid aggregation, monomers and oligomers are excellent targets to reduce neurotoxic brain damages for prevention of the disease progression, while oligomers and fibrils, abundant in the late stage of the disease, are pathological objectives to develop reliable imaging probes. So far, there have been many efforts to develop a wide variety of monovalent β-amyloid ligands such as thioflavin T, PIB, FDDNP, curcumin, and tramiprosate. However, pathology of Alzheimer's disease is not fully understood yet so that there is currently no cure and further investigations on Alzheimer's disease are needed. For past several years, multivalent β-amyloid ligands have offered an alternative route by enhancing binding affinity of drug candidates. In addition, it has been revealed that not only neurotoxicity due to the protein misfolding but also other factors are involved in the β-amyloid cascade such as oxidative stress, inflammation, metal chelation, and several types of neurotransmitters. Thus, there have been numerous studies to improve binding affinities of single β-amyloid ligands via adopting multivalent effects or to develop drug candidates targeting multiple stages of the pathological cascade. In this review, multivalent and multifunctional β-amyloid ligands and their promising aspects as an alternative approach to Alzheimer's disease are discussed.

AB - Ligands selectively targeting β-amyloid in the living brain are promising candidates of therapeutics and early diagnosis tools for Alzheimer's disease. Among the major stages of β-amyloid aggregation, monomers and oligomers are excellent targets to reduce neurotoxic brain damages for prevention of the disease progression, while oligomers and fibrils, abundant in the late stage of the disease, are pathological objectives to develop reliable imaging probes. So far, there have been many efforts to develop a wide variety of monovalent β-amyloid ligands such as thioflavin T, PIB, FDDNP, curcumin, and tramiprosate. However, pathology of Alzheimer's disease is not fully understood yet so that there is currently no cure and further investigations on Alzheimer's disease are needed. For past several years, multivalent β-amyloid ligands have offered an alternative route by enhancing binding affinity of drug candidates. In addition, it has been revealed that not only neurotoxicity due to the protein misfolding but also other factors are involved in the β-amyloid cascade such as oxidative stress, inflammation, metal chelation, and several types of neurotransmitters. Thus, there have been numerous studies to improve binding affinities of single β-amyloid ligands via adopting multivalent effects or to develop drug candidates targeting multiple stages of the pathological cascade. In this review, multivalent and multifunctional β-amyloid ligands and their promising aspects as an alternative approach to Alzheimer's disease are discussed.

UR - http://www.scopus.com/inward/record.url?scp=65549161050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549161050&partnerID=8YFLogxK

U2 - 10.2174/138161209787315648

DO - 10.2174/138161209787315648

M3 - Review article

C2 - 19199987

AN - SCOPUS:65549161050

VL - 15

SP - 637

EP - 658

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 6

ER -